Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057480 | 0.87 | PARP11 (0.42) | PARP11PARP10PARP1PDPK1CA12 | |
| SCHEMBL26512083 | 0.74 | TDP2 (0.38) | PARP11PARP10PARP1PDPK1CA12 | |
| SCHEMBL26345734 | 0.73 | PARP1 (0.38) | PARP11PARP10PARP1PDPK1CA12 | |
| SCHEMBL699630 | 0.73 | NPC1 (0.40) | PARP11PARP10PARP1CA12CA9 | |
| SCHEMBL11011352 | 0.72 | CA12 (0.45) | PARP11PARP10PARP1PDPK1CA12 | |
| SCHEMBL123760 | 0.71 | ALDH1A1 (0.32) | MEN1MAPTKMT2A | |
| SCHEMBL29419088 | 0.71 | ALDH1A1 (0.32) | MEN1MAPTKMT2A | |
| SCHEMBL21298564 | 0.71 | PARP1 (0.43) | PARP1MAPK1MEN1GAAMAPT | |
| SCHEMBL30124040 | 0.71 | NOS2 (0.40) | PARP11PARP10PARP1PDPK1CA12 | |
| SCHEMBL31116 | 0.69 | MEN1 (0.35) | GSK3BMAPK1MEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3761978-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2021-01-13 | — | — | EP | claimed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | claimed |
| EP-1540329-A4 | DRUG DISCOVERY METHOD | KEDDEM BIO SCIENCE LTD (IL) | 2009-06-10 | — | — | EP | claimed |
| JP-2006507480-A | — | — | 2006-03-02 | — | — | JP | claimed |
| EP-1540329-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-06-15 | — | — | EP | claimed |
| WO-2004010136-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2004-01-29 | — | — | WO | claimed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-3441072-B1 | ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCS | SEAGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3441072-A1 | ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCS | Seattle Genetics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3441072-A1 | ACTIVATED CARBON FILTRATION FOR PURIFICATION OF BENZODIAZEPINE ADCS | Seattle Genetics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-9987374-B2 | Cyclodextrin and antibody-drug conjugate formulations | SEATTLE GENETICS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-8019550-B2 | Drug discovery method | Keddem Bioscience Ltd. (IL) | 2011-09-13 | — | — | US | disclosed |
| EP-1540329-A4 | DRUG DISCOVERY METHOD | KEDDEM BIO SCIENCE LTD (IL) | 2009-06-10 | — | — | EP | disclosed |
| US-20050277117-A1 | Drug discovery method | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
| EP-1540329-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010136-A1 | DRUG DISCOVERY METHOD | KEDDEM BIO-SCIENCE LTD. (IL) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | PARP11 1717/4885PARP10 1254/4885PARP1 1148/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | PARP11 1717/4885PARP10 1254/4885PARP1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.